Literature DB >> 29987360

Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study.

Yong Eun Park1,2, Jae Hee Cheon3,4, Jae Jun Park5, Yoon Jae Kim6, Chang Hwan Choi7, Yehyun Park1,8, Soo Jung Park1,8, Tae Il Kim1,8, Won Ho Kim1,8.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is a rare progressive cholestatic liver disease of unknown causes, but is strongly associated with inflammatory bowel diseases (IBDs), particularly ulcerative colitis (UC). However, studies comparing risk factors and clinical courses of patients with concomitant UC and PSC with those of patients with PSC alone are lacking.
METHODS: We retrospectively reviewed patients with PSC diagnosed between 2005 and 2017 in four tertiary hospitals in Korea. We compared the risk factors and outcomes of concomitant UC and PSC (UC-PSC) and those of PSC alone.
RESULTS: PSC was diagnosed in 50 patients in four different tertiary hospitals in Korea. Of them, 18 patients (36.0%) had UC-PSC and 32 patients (64.0%) had PSC alone. The median age at PSC diagnosis was younger in the UC-PSC group than that in the PSC alone group (37 vs. 54 years, P = 0.002). In multivariate analysis, older age at PSC diagnosis (P = 0.007; odds ratio [OR], 0.884; 95% confidence interval [CI], 0.808-0.966) and current smoking habit (P = 0.033; OR, 0.026; 95% CI, 0.001-0.748) were determined to be independent factors for reducing the possibility of developing concomitant UC after PSC. Additionally, UC-PSC was shown to be an independent risk factor for the development of colorectal dysplasia (P = 0.044; OR, 10.829; 95% CI, 1.065-110.127).
CONCLUSIONS: Our analysis showed that UC-PSC is more likely to be negatively associated with current smoking and older age at the time of PSC diagnosis. Moreover, UC-PSC increased the risk of colorectal dysplasia.

Entities:  

Keywords:  Inflammatory bowel disease; Outcome assessment; Primary sclerosing cholangitis; Risk factor; Ulcerative colitis

Mesh:

Year:  2018        PMID: 29987360     DOI: 10.1007/s00384-018-3123-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  12 in total

1.  Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.

Authors:  Kirsten Boonstra; Karel J van Erpecum; Karin M J van Nieuwkerk; Joost P H Drenth; Alexander C Poen; Ben J M Witteman; Hans A R E Tuynman; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Inflamm Bowel Dis       Date:  2012-03-08       Impact factor: 5.325

2.  Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea.

Authors:  Byong Duk Ye; Suk-Kyun Yang; Sun-Jin Boo; Yun Kyung Cho; Dong-Hoon Yang; Soon Man Yoon; Kyung Jo Kim; Jeong-Sik Byeon; Seung-Jae Myung; Chang Sik Yu; Sung-Cheol Yun; Jin-Ho Kim
Journal:  Inflamm Bowel Dis       Date:  2010-12-16       Impact factor: 5.325

3.  Primary Sclerosing Cholangitis.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  N Engl J Med       Date:  2016-12-22       Impact factor: 91.245

4.  Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population.

Authors:  K M Boberg; E Aadland; J Jahnsen; N Raknerud; M Stiris; H Bell
Journal:  Scand J Gastroenterol       Date:  1998-01       Impact factor: 2.423

5.  Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.

Authors:  J Ludwig; S S Barham; N F LaRusso; L R Elveback; R H Wiesner; J T McCall
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

6.  Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.

Authors:  Montserrat Fraga; Nicolas Fournier; Ekaterina Safroneeva; Valérie Pittet; Sébastien Godat; Alex Straumann; Andreas Nydegger; Stephan R Vavricka; Darius Moradpour; Alain M Schoepfer
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-01       Impact factor: 2.566

Review 7.  Primary Sclerosing Cholangitis.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

Review 8.  Primary sclerosing cholangitis.

Authors:  Gideon M Hirschfield; Tom H Karlsen; Keith D Lindor; David H Adams
Journal:  Lancet       Date:  2013-06-28       Impact factor: 79.321

9.  Clinical course of primary sclerosing cholangitis and concomitant ulcerative colitis - a preliminary report of retrospective study among patients from Southern Poland.

Authors:  Mikołaj K Głowacki; Małgorzata Zwolińska-Wcisło; Paulina Frączek; Martyna Gomulska; Danuta Owczarek; Dorota Cibor; Andrzej Cieśla; Tomasz Mach
Journal:  Folia Med Cracov       Date:  2015

Review 10.  Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.

Authors:  Carolina Palmela; Farhad Peerani; Daniel Castaneda; Joana Torres; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

View more
  1 in total

1.  Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.

Authors:  Lucas Guillo; Ferdinando D'Amico; Mélanie Serrero; Karine Angioi; Damien Loeuille; Antonio Costanzo; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-08-10       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.